PP
CRNX icon

Paloma Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

Paloma Partners’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-8,369
Closed -$210K – 1389
2019
Q4 		$210K Buy
+8,369
New +$159K ﹤0.01% 1949

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Paloma Partners's CRNX Position: Q1 2020 in Review

Paloma Partners sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2020, closing a stake of 8,369 shares — an estimated $210K sold.

Paloma Partners first reported a position in CRNX in Q4 2019 and held it in 1 quarter. The position peaked at $210K in Q4 2019. 56 funds tracked by Wall St. Rank hold CRNX as of Q1 2020.

  • Paloma Partners reported no remaining Crinetics Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Paloma Partners sold 8,369 Crinetics Pharmaceuticals shares in Q1 2020, an estimated $210K.
  • Paloma Partners first reported a position in Crinetics Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Paloma Partners's Crinetics Pharmaceuticals position peaked at $210K in Q4 2019.
  • 56 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2020.

Based on Paloma Partners's 13F filing for Q1 2020, filed 15 May 2020.